Western General Hospital, NHS Lothian
Welcome,         Profile    Billing    Logout  
 10 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dixit, Sanjay
ARISTOCRAT, NCT05629702: Blinded Trial of Temozolomide +/- Cannabinoids

Recruiting
2
234
Europe
Nabiximols, Sativex, Temozolomide, Nabiximols-matched placebo
University of Birmingham, University of Leeds, The Brain Tumour Charity, Jazz Pharmaceuticals
Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
02/26
02/27
TRAP-AF, NCT05185310: Strategies in Patients Undergoing Repeat AF Ablation

Terminated
N/A
8
US
Ablation
University of Pennsylvania
Atrial Fibrillation
02/23
02/23
Erridge, Sara
ARISTOCRAT, NCT05629702: Blinded Trial of Temozolomide +/- Cannabinoids

Recruiting
2
234
Europe
Nabiximols, Sativex, Temozolomide, Nabiximols-matched placebo
University of Birmingham, University of Leeds, The Brain Tumour Charity, Jazz Pharmaceuticals
Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
02/26
02/27
Symeonides, Stefan
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
ST101-101, NCT04478279 / 2019-004213-13: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
125
Europe, US
ST101, Temozolomide, Radiation
Sapience Therapeutics
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
12/24
12/25
CAPER, NCT04262427 / 2018-004314-17: The Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

Recruiting
1/2
21
Europe
Cyclophosphamide 50mg, cyclophosphamide monohydrate, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], Keytruda, MK-3475
The Christie NHS Foundation Trust, Merck Sharp & Dohme LLC, Liverpool Clinical Trials Centre, University of Manchester
Metastatic Renal Cell Carcinoma
10/23
04/24
NCT04990479: Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma

Active, not recruiting
1b
34
Europe
GAd-PEV, MVA-PEV
Nouscom SRL
Melanoma (Skin), Non-Small-Cell Lung Carcinoma
10/24
10/24
SGNCEA5C-001, NCT06131840: A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

Recruiting
1
410
Europe, Canada, US
PF-08046050, SAR445953; SGN-CEACAM5C
Seagen Inc., Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
03/29
03/30
NCT06551142: A Study of GSK5764227 in Participants With. Advanced Solid Tumors

Recruiting
1
240
Canada, Japan, US, RoW
GSK5764227, Cisplatin, Carboplatin, Atezolizumab, Pembrolizumab, Durvalumab, Fluorouracil, Folinic acid, Cetuximab, Bevacizumab
GlaxoSmithKline
Neoplasms
07/26
03/27
TARGET National, NCT04723316: Tumour Characterisation to Guide Experimental Targeted Therapy - National

Recruiting
N/A
6000
Europe
The Christie NHS Foundation Trust
Cancer
01/26
01/28
Seville, Katie
ASPIRE-ILD, NCT03485378: Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease

Active, not recruiting
N/A
39
Europe, Canada
Stereotactic Ablative Radiotherapy
Lawson Health Research Institute, London Health Sciences Centre, University of British Columbia, Western University, Canada
Non Small Cell Lung Cancer, Interstitial Lung Disease
01/22
09/26
Nowicki, Stefan
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
ARISTOCRAT, NCT05629702: Blinded Trial of Temozolomide +/- Cannabinoids

Recruiting
2
234
Europe
Nabiximols, Sativex, Temozolomide, Nabiximols-matched placebo
University of Birmingham, University of Leeds, The Brain Tumour Charity, Jazz Pharmaceuticals
Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
02/26
02/27

Download Options